Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Takeda Submits Plans to Improve Business Practices
Takeda Pharmaceutical submitted plans to mend its business practices on July 10 after it received a business improvement order over its misleading advertisements last month. The leading Japanese drug maker posted the details of the plans on its website on…
To read the full story
Related Article
- Takeda Announces Its Plan to Improve Business Practices; Will Add an Outside Expert to Review Board
July 14, 2015
- Takeda to Submit Plans to Improve Business Operations after MHLW Order
June 15, 2015
- Takeda Slapped with Business Improvement Order over CASE-J
June 12, 2015
- No Problems Found with Integrity of CASE-J Data Analyses: Kyoto Univ.
March 2, 2015
- Takeda Directors Face 3-Month Pay Cut over CASE-J Issue
October 6, 2014
- MHLW to Conduct Hearings over CASE-J Study, Take “Appropriate Action” against Takeda: Minister
June 27, 2014
- Probe Finds Takeda’s Systematic Involvement in CASE-J Study, No Data Tampering
June 23, 2014
- JPMA Urges Takeda to Improve Promotion Regime over CASE-J
March 24, 2014
- Trial Investigators Brush Aside Concerns over CASE-J in US Journal
March 18, 2014
- MHLW to Conduct Hearings with Takeda on Blopress Research Data
March 5, 2014
- Takeda Extended 3.7 Billion Yen in CASE-J-Linked Grants to Kyoto Univ., 2 Entities; “No COI” Says Pres. Hasegawa
March 4, 2014
- Takeda Apologizes for Violating Promotion Code, Inappropriate Expressions in Ads
March 4, 2014
- Japanese Cardiologist Raises Statistical Concerns over CASE-J Study in US Journal
February 28, 2014
- Takeda Offered 600 M. Yen in Grants to Kyoto University Involved in CASE-J Study, Where Ex-Employee Affiliated
December 5, 2013
BUSINESS
- Kyowa Kirin Targets 20-Plus New Pipeline Assets by Early 2030s
February 10, 2026
- Kyowa Kirin’s FY2025 Core Operating Profit Hits Record High as Costs Fall
February 10, 2026
- Eisai CFO Casts Oncology Pipeline Expansion as Urgent Task
February 10, 2026
- Pharma Fears Off-Year Price Reform Loses Traction after LDP Sweep
February 10, 2026
- Chugai’s Hemlibra Successor Shows Promise in PI/II Study
February 10, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…